Talphera (TLPH) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 11, 2021
Document Information [Line Items]
Entity Central Index Key	0001427925
Entity Registrant Name	ACELRX PHARMACEUTICALS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-35068
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-2193603
Entity Address, Address Line One	25821 Industrial Boulevard, Suite 400
Entity Address, City or Town	Hayward
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94545
City Area Code	650
Local Phone Number	216-3500
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ACRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		119,179,806

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 26,327	$ 27,274	[1]
Short-term investments	28,998	15,612	[1]
Accounts receivable, net	104	635	[1]
Inventories, net	1,363	1,626	[1]
Prepaid expenses and other current assets	2,178	1,683	[1]
Total current assets	58,970	46,830	[1]
Operating lease right-of-use assets	4,607	3,150	[1]
Property and equipment, net	15,939	15,659	[1]
Other assets	70	656	[1]
Total Assets	79,586	66,295	[1]
Current Liabilities:
Accounts payable	1,941	2,737	[1]
Accrued and other liabilities	3,980	5,045	[1]
Long-term debt, current portion	8,764	8,735	[1]
Operating lease liabilities, current portion	503	1,118	[1]
Total current liabilities	15,188	17,635	[1]
Long-term debt, net of current portion	9,374	13,140	[1]
Operating lease liabilities, net of current portion	4,115	2,606	[1]
Liability related to the sale of future royalties, net of current portion	86,770	88,365	[1]
Other long-term liabilities	128	299	[1]
Total liabilities	115,575	122,045	[1]
Commitments and Contingencies
Stockholders’ Deficit:
Common stock, $0.001 par value—200,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 119,179,806 and 98,812,008 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	119	98	[1]
Additional paid-in capital	421,184	382,637	[1]
Accumulated deficit	(457,292)	(438,485)	[1]
Total stockholders’ deficit	(35,989)	(55,750)	[1]
Total Liabilities and Stockholders’ Deficit	$ 79,586	$ 66,295	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	119,179,806	98,812,008
Common stock, shares outstanding (in shares)	119,179,806	98,812,008

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Revenue	$ 443	$ 2,924	$ 954	$ 3,310
Operating costs and expenses:
Cost of goods sold	1,040	1,370	2,080	2,881
Research and development	724	813	1,693	2,225
Selling, general and administrative	8,694	7,575	16,338	20,886
Total operating costs and expenses	10,458	9,758	20,111	25,992
Loss from operations	(10,015)	(6,834)	(19,157)	(22,682)
Other income:
Interest expense	(614)	(872)	(1,286)	(1,727)
Interest income and other (expense) income, net	(16)	270	60	205
Non-cash interest income on liability related to future sale of royalties	799	834	1,581	1,677
Total other income	169	232	355	155
Net loss before income taxes	(9,846)	(6,602)	(18,802)	(22,527)
Provision for income taxes	(5)	(4)	(5)	(4)
Net loss	(9,851)	(6,606)	(18,807)	(22,531)
Comprehensive loss	$ (9,851)	$ (6,606)	$ (18,807)	$ (22,531)
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)	$ (0.16)	$ (0.28)
Shares used in computing net loss per share of common stock, basic and diluted – See Note 11 (in shares)	119,120,040	80,661,853	116,204,492	80,359,679
Product [Member]
Revenue:
Revenue	$ 392	$ 303	$ 843	$ 577
Contract and Other Collaboration [Member]
Revenue:
Revenue	$ 51	$ 2,621	$ 111	$ 2,733

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019	79,573,101
Balance at Dec. 31, 2019	$ 79	$ 356,609	$ (398,106)	$ (41,418)
Stock-based compensation		1,146		1,146
Restricted stock units vested (in shares)	216,399
Tax payments related to shares withheld for restricted stock units vested		(86)		(86)
Net proceeds from issuance of common stock in connection with equity financings (in shares)	431,800
Net proceeds from issuance of common stock in connection with equity financings	$ 1	783		784
Issuance of common stock upon ESPP purchase (in shares)	194,451
Issuance of common stock upon ESPP purchase		218		218
Net loss			(15,925)	(15,925)
Balance (in shares) at Mar. 31, 2020	80,415,751
Balance at Mar. 31, 2020	$ 80	358,670	(414,031)	(55,281)
Balance (in shares) at Dec. 31, 2019	79,573,101
Balance at Dec. 31, 2019	$ 79	356,609	(398,106)	(41,418)
Net loss				(22,531)
Balance (in shares) at Jun. 30, 2020	80,890,185
Balance at Jun. 30, 2020	$ 80	360,425	(420,637)	(60,132)
Balance (in shares) at Mar. 31, 2020	80,415,751
Balance at Mar. 31, 2020	$ 80	358,670	(414,031)	(55,281)
Stock-based compensation		1,090		1,090
Restricted stock units vested (in shares)	29,434
Net proceeds from issuance of common stock in connection with equity financings (in shares)	445,000
Net proceeds from issuance of common stock in connection with equity financings		665		665
Net loss			(6,606)	(6,606)
Balance (in shares) at Jun. 30, 2020	80,890,185
Balance at Jun. 30, 2020	$ 80	360,425	(420,637)	(60,132)
Balance (in shares) at Dec. 31, 2020	98,812,008
Balance at Dec. 31, 2020	$ 98	382,637	(438,485)	(55,750)	[1]
Stock-based compensation		1,089		1,089
Restricted stock units vested (in shares)	404,172
Tax payments related to shares withheld for restricted stock units vested		(249)		(249)
Net proceeds from issuance of common stock in connection with equity financings (in shares)	19,701,562
Net proceeds from issuance of common stock in connection with equity financings	$ 20	36,340		36,360
Issuance of common stock upon ESPP purchase (in shares)	183,132
Issuance of common stock upon ESPP purchase		192		192
Issuance of common stock upon exercise of stock options (in shares)	2,125
Issuance of common stock upon exercise of stock options		2		2
Net loss			(8,956)	(8,956)
Balance (in shares) at Mar. 31, 2021	119,102,999
Balance at Mar. 31, 2021	$ 118	420,011	(447,441)	(27,312)
Balance (in shares) at Dec. 31, 2020	98,812,008
Balance at Dec. 31, 2020	$ 98	382,637	(438,485)	(55,750)	[1]
Net loss				(18,807)
Balance (in shares) at Jun. 30, 2021	119,179,806
Balance at Jun. 30, 2021	$ 119	421,184	(457,292)	(35,989)
Balance (in shares) at Mar. 31, 2021	119,102,999
Balance at Mar. 31, 2021	$ 118	420,011	(447,441)	(27,312)
Stock-based compensation		1,172		1,172
Restricted stock units vested (in shares)	74,438
Issuance of common stock upon exercise of stock options (in shares)	2,369
Issuance of common stock upon exercise of stock options	$ 1	1		2
Net loss			(9,851)	(9,851)
Balance (in shares) at Jun. 30, 2021	119,179,806
Balance at Jun. 30, 2021	$ 119	$ 421,184	$ (457,292)	$ (35,989)
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		69 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (9,851)	$ (8,956)	$ (6,606)	$ (15,925)	$ (18,807)	$ (22,531)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to royalty monetization					(83)	(121)
Non-cash interest income on liability related to royalty monetization	(799)		(834)		(1,581)	(1,677)	$ 26,644
Depreciation and amortization					1,029	979
Non-cash interest expense related to debt financing					430	558
Stock-based compensation					2,261	2,236
Other					(61)	341
Changes in operating assets and liabilities:
Accounts receivable					531	237
Inventories					143	277
Prepaid expenses and other assets					(277)	94
Accounts payable					(65)	675
Accrued liabilities					(963)	(1,779)
Operating lease liabilities					(563)	(442)
Deferred revenue					(49)	(2,901)
Net cash used in operating activities					(18,055)	(24,054)
Cash flows from investing activities:
Purchase of property and equipment					(1,615)	(170)
Purchase of investments					(38,201)	(28,807)
Proceeds from maturities of investments					24,784	58,555
Net cash (used in) provided by investing activities					(15,032)	29,578
Cash flows from financing activities:
Payment of long-term debt					(4,167)	0
Net proceeds from issuance of common stock in connection with equity financings					36,360	1,449
Net proceeds from issuance of common stock through equity plans					196	218
Payment of employee tax obligations related to vesting of restricted stock units					(249)	(86)
Net cash provided by financing activities					32,140	1,581
Net (decrease) increase in cash and cash equivalents					(947)	7,105
Cash and cash equivalents—Beginning of period		$ 27,274		$ 14,684	27,274	14,684
Cash and cash equivalents—End of period	$ 26,327		$ 21,789		$ 26,327	$ 21,789	$ 26,327

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. The Company AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 January 2006, AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA® November 2, 2018, first 2019. June 2018, not may one July 2021, 12 May 12, 2021 ( Termination of Gr nenthal Agreements July 2021, 10 3 10 50 12 The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of June 30, 2021 December 31, 2020, one 10 September 18, 2015, August 31, 2020, third DSUVIA/DZUVEO DSUVIA, known as DZUVEO in Europe, approved by the FDA in November 2018 June 2018, DSUVIA was approved with a Risk Evaluation and Mitigation Strategy, or REMS, which restricts distribution to certified medically supervised healthcare settings in order to prevent respiratory depression resulting from accidental exposure. DSUVIA is only distributed to facilities certified in the DSUVIA REMS program following attestation by an authorized representative to comply with appropriate dispensing and use restrictions of DSUVIA. To become certified, a healthcare setting is required to train their healthcare professionals on the proper use of DSUVIA and have the ability to manage respiratory depression. DSUVIA is not Zalviso Zalviso delivers 15 September 2013 July 25, 2014. IAP312, IAP312 August 2017, three 3 Termination of Grünenthal Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 13, 2020. May 12, 2021 May 12, 2021. Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note 7 Reclassifications Certain prior period amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current period's presentation. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and the rules and regulations of the SEC. Accordingly, they do not Operating results for the three six June 30, 2021, not may December 31, 2021. December 31, 2020, December 31, 2020, 10 10 December 31, 2020, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not Significant Accounting Policies The Company’s significant accounting policies are detailed in its Annual Report on Form 10 December 31, 2020. no three six June 30, 2021, 2020 10 Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments Credit Losses, 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022. not

Note 2 - Investments and Fair V

Note 2 - Investments and Fair Value Measurement	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Investments and Fair Value Measurement Disclosure [Text Block]	2. Investments The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). Marketable securities which have maturities beyond one The table below summarizes the Company’s cash, cash equivalents and short-term investments (in thousands): As of June 30, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 1,114 $ — $ — $ 1,114 Money market funds 25,213 — — 25,213 Total cash and cash equivalents 26,327 — — 26,327 Short-term investments: Commercial paper 24,436 — — 24,436 Corporate debt securities 4,562 — — 4,562 Total short-term investments 28,998 — — 28,998 Total cash, cash equivalents and short-term investments $ 55,325 $ — $ — $ 55,325 As of December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 5,181 $ — $ — $ 5,181 Money market funds 3,996 — — 3,996 Commercial paper 18,097 — — 18,097 Total cash and cash equivalents 27,274 — — 27,274 Short-term investments: U.S. government agency securities 5,818 — — 5,818 Commercial paper 9,794 — — 9,794 Total short-term investments 15,612 — — 15,612 Total cash, cash equivalents and short-term investments $ 42,886 $ — $ — $ 42,886 There were no other-than-temporary impairments for these securities at June 30, 2021 December 31, 2020. no three six June 30, 2021 2020. As of June 30, 2021, December 31, 2020, one Fair Value Measurement The Company’s financial instruments consist of Level I and II assets and Level III liabilities. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 third June 30, 2021, December 31, 2020, 5 two The following table sets forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): As of June 30, 2021 Fair Value Level I Level II Level III Assets Money market funds $ 25,213 $ 25,213 $ — $ — Commercial paper 24,436 — 24,436 — Corporate debt securities 4,562 — 4,562 — Total assets measured at fair value $ 54,211 $ 25,213 $ 28,998 $ — Liabilities Contingent put option liability $ 128 $ — $ — $ 128 Total liabilities measured at fair value $ 128 $ — $ — $ 128 As of December 31, 2020 Fair Value Level I Level II Level III Assets Money market funds $ 3,996 $ 3,996 $ — $ — U.S. government agency securities 5,818 — 5,818 — Commercial paper 27,891 — 27,891 — Total assets measured at fair value $ 37,705 $ 3,996 $ 33,709 $ — Liabilities Contingent put option liability $ 246 $ — $ — $ 246 Total liabilities measured at fair value $ 246 $ — $ — $ 246 The following tables set forth a summary of the changes in the fair value of the Company’s Level III financial liabilities for the three six June 30, 2021 2020 Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 Fair value—beginning of period $ 181 $ 246 Change in fair value of contingent put option associated with the Loan Agreement (53 ) (118 ) Fair value—end of period $ 128 $ 128 Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Fair value—beginning of period $ 746 $ 437 Change in fair value of contingent put option associated with the Loan Agreement (155 ) 154 Fair value—end of period $ 591 $ 591

Note 3 - Inventories, Net

Note 3 - Inventories, Net	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or net realizable value and consist of the following (in thousands): Balance as of June 30, 2021 December 31, 2020 Raw materials $ 277 $ 257 Work-in-process — 30 Finished goods 1,086 1,339 Total $ 1,363 $ 1,626 The Company recorded inventory impairment charges of $0 and $0.1 million for the three six June 30, 2021, three six June 30, 2020, six June 30, 2020, may

Note 4 - Revenue From Contracts

Note 4 - Revenue From Contracts With Customers	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4. The following table summarizes revenue from contracts with customers for the three six June 30, 2021 2020 Three months ended June 30, 2021 Six months ended June 30, 2021 Product sales: DSUVIA $ 392 $ 573 Zalviso — 270 Total product sales 392 843 Contract and collaboration revenue: Non-cash royalty revenue related to Royalty Monetization (Note 7) 38 83 Royalty revenue 13 28 Total revenues from contract and other collaboration 51 111 Total revenue $ 443 $ 954 Three months ended June 30, 2020 Six months ended June 30, 2020 Product sales: DSUVIA $ 2 $ 157 Zalviso 301 420 Total product sales 303 577 Contract and collaboration revenue: Non-cash royalty revenue related to Royalty Monetization (Note 7) 37 121 Royalty revenue 12 40 Other revenue 2,572 2,572 Total revenues from contract and other collaboration 2,621 2,733 Total revenue $ 2,924 $ 3,310 For additional details on the Company’s accounting policy regarding revenue recognition, refer to Note 1 10 December 31, 2020. Product Sales The Company’s commercial launch of DSUVIA in the United States occurred in the first 2019. May 12, 2021. Contract and Other Collaboration Contract and other collaboration revenue includes revenue under the Grünenthal Agreements related to research and development services, non-cash royalty revenue related to the Royalty Monetization and royalty revenue for sales of Zalviso in Europe. Contract Liability The following table presents changes in the Company’s contract liability for the six June 30, 2021 ( Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liability: Deferred revenue – Grünenthal Agreements $ 49 $ — $ (49 ) $ — Deferred revenue $ 49 $ — $ (49 ) $ — For the three six June 30, 2021 2020, Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ — $ 154 $ 49 $ 233 Performance obligations eliminated upon termination — 2,572 — 2,572 New activities in the period from performance obligations satisfied: Performance obligations satisfied — 147 221 187 Total revenue from performance obligations satisfied or eliminated $ — $ 2,873 $ 270 $ 2,992

Note 5 - Long-term Debt

Note 5 - Long-term Debt	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Long-term Debt [Text Block]	5. Loan Agreement with Oxford On May 30, 2019, May 30, 2019. In connection with the Loan Agreement, on May 30, 2019, As of June 30, 2021, three six June 30, 2021, three six June 30, 2020, Non-Interest Bearing Payments for the Construction of Leasehold Improvements In August 2019, may four July 2022. June 30, 2021, June 30, 2021

Note 6 - Leases

Note 6 - Leases	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. Office Leases The Company leased office and laboratory space for its corporate headquarters, located at 301 351 On March 26, 2021, April 30, 2021. six June 30, 2021. April 30, 2021, six June 30, 2021. On March 26, 2021, 25821 April 1, 2021. two three one Contract Manufacturing Leases On April 21, 2021, March 31, 2021, 30 The term of the CSA is for a period of five first two one 24 The Company will pay Catalent an annual fee of $1.0 million beginning January 1, 2022. 10 December 31, 2022, may January 1 January 1, 2023, The Company has determined that the fixed fees in the CSA are in-substance lease payments. The Company concluded that this agreement contains an embedded lease as the clean rooms have been built specifically for production of the Company’s product and their use is effectively controlled by the Company as it has sole use over the space during the term of the agreement. The Company accounts for the agreement as an operating lease and has evaluated the non-cancelable lease term to be through the binding commitment date of May 15, 2027. In addition, the Company has entered into an agreement for commercial supply manufacturing services related to the Company’s Zalviso drug product with a contract manufacturing organization, which it accounts for as an operating lease. The components of lease expense are presented in the following table (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease costs $ 440 $ 269 $ 780 $ 609 Gain on derecognition of operating lease — — (522 ) — Sublease income (50 ) (149 ) (199 ) (299 ) Loss on termination of sublease 331 — 331 — Net lease costs $ 721 $ 120 $ 390 $ 310 The weighted average remaining lease term and discount rate related to the operating leases are presented in the following table: June 30, 2021 Weighted-average remaining term – operating lease (in years) 5.41 Weighted-average discount rate – operating lease 12.80 % Future minimum lease payments as of June 30, 2021 Year: 2021 (remaining nine months) $ 407 2022 1,483 2023 1,144 2024 1,040 2025 1,040 Thereafter 1,454 Total future minimum lease payments 6,568 Less imputed interest (2,453 ) Total $ 4,115 Reported as: Operating lease liabilities $ 4,618 Operating lease liabilities, current portion (503 ) Operating lease liabilities, net of current portion $ 4,115

Note 7 - Liability Related to S

Note 7 - Liability Related to Sale of Future Royalties	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Liability Related To Sale Of Future Royalties Disclosure [Text Block]	7. In September 2015, first four 80% The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company’s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. During the three June 30, 2020, November 13, 2020. May 12, 2021 May 12, 2021. may The effective interest rate over the life of the liability will be 0% as we record interest income over the remaining term of the arrangement as an offset to the interest expense that was recognized in prior periods. The effective interest income rate for each of the three six June 30, 2021 2020, The following table shows the activity within the liability account for the six June 30, 2021 ( Six months ended June 30, 2021 Period from inception to June 30, 2021 Liability related to sale of future royalties — beginning balance $ 88,471 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue (120 ) (1,058 ) Non-cash interest (income) expense recognized (1,581 ) 26,644 Liability related to sale of future royalties as of June 30, 2021 86,770 86,770 Less: current portion — — Liability related to sale of future royalties — net of current portion $ 86,770 $ 86,770 As royalties are remitted to SWK from ARPI LLC, as described in Note 1 10 December 31, 2020,

Note 8 - Legal Proceedings

Note 8 - Legal Proceedings	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Legal Matters and Contingencies [Text Block]	8. On June 8, 2021, 10 20 10b 5 August 9, 2021 December 16, 2021. On July 6, 2021, The Company believes that these lawsuits are without merit, and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Equity Common Stock Underwritten Public Offering On January 22, 2021, January 27, 2021, ATM Agreement The Company has entered into a Controlled Equity Offering SM may During the three six June 30, 2021, three six June 30, 2020, June 30, 2021, may Amended Stock Plan Amended 2020 On June 17, 2021, 2021 2020 2020 2020 may 2020 not 2020 2020 2011 may 2020 2020

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. The Company recorded total stock-based compensation expense for stock options, stock awards and awards made under the Amended 2011 Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cost of goods sold $ 21 $ 27 $ 43 $ 73 Research and development 200 184 381 384 Selling, general and administrative 951 879 1,837 1,779 Total $ 1,172 $ 1,090 $ 2,261 $ 2,236 As of June 30, 2021,

Note 11 - Net Loss Per Share of

Note 11 - Net Loss Per Share of Common Stock	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	11. The Company’s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, RSUs, and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock as their effect is antidilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive: June 30, 2021 2020 ESPP, RSUs and stock options to purchase common stock 16,907,412 14,816,721 Common stock warrants 176,679 176,679

Note 12 - Subsequent Events

Note 12 - Subsequent Events	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	12. Out-License Agreement (DZUVEO) On July 14, 2021, The DZUVEO Agreement has an initial term of ten first December 31 December 31, 2022, January 1, 2022 April 30, 2022). five not six 6 The Company is entitled to receive up to € 47.0 Beginning in the third third The DZUVEO Agreement also provides Aguettant with a right of first eighteen 18 In-License Agreement On July 14, 2021, 10 3 10 50 The PFS Agreement has an initial term of ten first December 31 first December 31 first January 1 April 30 five not six 6 Aguettant is entitled to receive up to $24.0 million in sales-based milestone payments. The Company will purchase each product from Aguettant at an agreed price, or the PFS Purchase Price, subject to adjustment. The Company will also make revenue share payments that, combined with the PFS Purchase Price, will range from 40% to 45% of net sales in the United States. The Company and Aguettant will agree on minimum sales obligations twelve The Company has the right to grant sublicenses to its affiliates or, with the prior approval of Aguettant, third

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Business Description of Entity [Policy Text Block]	The Company AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 January 2006, AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA® November 2, 2018, first 2019. June 2018, not may one July 2021, 12 May 12, 2021 ( Termination of Gr nenthal Agreements July 2021, 10 3 10 50 12 The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of June 30, 2021 December 31, 2020, one 10 September 18, 2015, August 31, 2020, third DSUVIA/DZUVEO DSUVIA, known as DZUVEO in Europe, approved by the FDA in November 2018 June 2018, DSUVIA was approved with a Risk Evaluation and Mitigation Strategy, or REMS, which restricts distribution to certified medically supervised healthcare settings in order to prevent respiratory depression resulting from accidental exposure. DSUVIA is only distributed to facilities certified in the DSUVIA REMS program following attestation by an authorized representative to comply with appropriate dispensing and use restrictions of DSUVIA. To become certified, a healthcare setting is required to train their healthcare professionals on the proper use of DSUVIA and have the ability to manage respiratory depression. DSUVIA is not Zalviso Zalviso delivers 15 September 2013 July 25, 2014. IAP312, IAP312 August 2017, three 3 Termination of Grünenthal Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 13, 2020. May 12, 2021 May 12, 2021.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note 7
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain prior period amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current period's presentation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and the rules and regulations of the SEC. Accordingly, they do not Operating results for the three six June 30, 2021, not may December 31, 2021. December 31, 2020, December 31, 2020, 10 10 December 31, 2020,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments Credit Losses, 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022. not

Note 2 - Investments and Fair_2

Note 2 - Investments and Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	As of June 30, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 1,114 $ — $ — $ 1,114 Money market funds 25,213 — — 25,213 Total cash and cash equivalents 26,327 — — 26,327 Short-term investments: Commercial paper 24,436 — — 24,436 Corporate debt securities 4,562 — — 4,562 Total short-term investments 28,998 — — 28,998 Total cash, cash equivalents and short-term investments $ 55,325 $ — $ — $ 55,325 As of December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 5,181 $ — $ — $ 5,181 Money market funds 3,996 — — 3,996 Commercial paper 18,097 — — 18,097 Total cash and cash equivalents 27,274 — — 27,274 Short-term investments: U.S. government agency securities 5,818 — — 5,818 Commercial paper 9,794 — — 9,794 Total short-term investments 15,612 — — 15,612 Total cash, cash equivalents and short-term investments $ 42,886 $ — $ — $ 42,886
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	As of June 30, 2021 Fair Value Level I Level II Level III Assets Money market funds $ 25,213 $ 25,213 $ — $ — Commercial paper 24,436 — 24,436 — Corporate debt securities 4,562 — 4,562 — Total assets measured at fair value $ 54,211 $ 25,213 $ 28,998 $ — Liabilities Contingent put option liability $ 128 $ — $ — $ 128 Total liabilities measured at fair value $ 128 $ — $ — $ 128 As of December 31, 2020 Fair Value Level I Level II Level III Assets Money market funds $ 3,996 $ 3,996 $ — $ — U.S. government agency securities 5,818 — 5,818 — Commercial paper 27,891 — 27,891 — Total assets measured at fair value $ 37,705 $ 3,996 $ 33,709 $ — Liabilities Contingent put option liability $ 246 $ — $ — $ 246 Total liabilities measured at fair value $ 246 $ — $ — $ 246
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 Fair value—beginning of period $ 181 $ 246 Change in fair value of contingent put option associated with the Loan Agreement (53 ) (118 ) Fair value—end of period $ 128 $ 128 Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Fair value—beginning of period $ 746 $ 437 Change in fair value of contingent put option associated with the Loan Agreement (155 ) 154 Fair value—end of period $ 591 $ 591

Note 3 - Inventories, Net (Tabl

Note 3 - Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Balance as of June 30, 2021 December 31, 2020 Raw materials $ 277 $ 257 Work-in-process — 30 Finished goods 1,086 1,339 Total $ 1,363 $ 1,626

Note 4 - Revenue From Contrac_2

Note 4 - Revenue From Contracts With Customers (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three months ended June 30, 2021 Six months ended June 30, 2021 Product sales: DSUVIA $ 392 $ 573 Zalviso — 270 Total product sales 392 843 Contract and collaboration revenue: Non-cash royalty revenue related to Royalty Monetization (Note 7) 38 83 Royalty revenue 13 28 Total revenues from contract and other collaboration 51 111 Total revenue $ 443 $ 954 Three months ended June 30, 2020 Six months ended June 30, 2020 Product sales: DSUVIA $ 2 $ 157 Zalviso 301 420 Total product sales 303 577 Contract and collaboration revenue: Non-cash royalty revenue related to Royalty Monetization (Note 7) 37 121 Royalty revenue 12 40 Other revenue 2,572 2,572 Total revenues from contract and other collaboration 2,621 2,733 Total revenue $ 2,924 $ 3,310
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liability: Deferred revenue – Grünenthal Agreements $ 49 $ — $ (49 ) $ — Deferred revenue $ 49 $ — $ (49 ) $ — Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ — $ 154 $ 49 $ 233 Performance obligations eliminated upon termination — 2,572 — 2,572 New activities in the period from performance obligations satisfied: Performance obligations satisfied — 147 221 187 Total revenue from performance obligations satisfied or eliminated $ — $ 2,873 $ 270 $ 2,992

Note 6 - Leases (Tables)

Note 6 - Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease costs $ 440 $ 269 $ 780 $ 609 Gain on derecognition of operating lease — — (522 ) — Sublease income (50 ) (149 ) (199 ) (299 ) Loss on termination of sublease 331 — 331 — Net lease costs $ 721 $ 120 $ 390 $ 310 June 30, 2021 Weighted-average remaining term – operating lease (in years) 5.41 Weighted-average discount rate – operating lease 12.80 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year: 2021 (remaining nine months) $ 407 2022 1,483 2023 1,144 2024 1,040 2025 1,040 Thereafter 1,454 Total future minimum lease payments 6,568 Less imputed interest (2,453 ) Total $ 4,115 Operating lease liabilities $ 4,618 Operating lease liabilities, current portion (503 ) Operating lease liabilities, net of current portion $ 4,115

Note 7 - Liability Related to_2

Note 7 - Liability Related to Sale of Future Royalties (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Other Liabilities [Table Text Block]	Six months ended June 30, 2021 Period from inception to June 30, 2021 Liability related to sale of future royalties — beginning balance $ 88,471 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue (120 ) (1,058 ) Non-cash interest (income) expense recognized (1,581 ) 26,644 Liability related to sale of future royalties as of June 30, 2021 86,770 86,770 Less: current portion — — Liability related to sale of future royalties — net of current portion $ 86,770 $ 86,770

Note 10 - Stock-based Compens_2

Note 10 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cost of goods sold $ 21 $ 27 $ 43 $ 73 Research and development 200 184 381 384 Selling, general and administrative 951 879 1,837 1,779 Total $ 1,172 $ 1,090 $ 2,261 $ 2,236

Note 11 - Net Loss Per Share _2

Note 11 - Net Loss Per Share of Common Stock (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30, 2021 2020 ESPP, RSUs and stock options to purchase common stock 16,907,412 14,816,721 Common stock warrants 176,679 176,679

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Cash, Cash Equivalents, and Short-term Investments, Total	$ 55.3	$ 42.9

Note 2 - Investments and Fair_3

Note 2 - Investments and Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities, Total	$ 0		$ 0
Debt Securities, Available-for-sale, Realized Gain (Loss), Total	$ 0	$ 0

Note 2 - Investments and Fair_4

Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Amortized Cost	$ 55,325	$ 42,886
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	55,325	42,886
Cash and Cash Equivalents [Member]
Amortized Cost	26,327	27,274
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	26,327	27,274
Cash and Cash Equivalents [Member] | Cash [Member]
Amortized Cost	1,114	5,181
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	1,114	5,181
Cash and Cash Equivalents [Member] | Money Market Funds [Member]
Amortized Cost	25,213	3,996
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	25,213	3,996
Cash and Cash Equivalents [Member] | Commercial Paper [Member]
Amortized Cost	24,436	18,097
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	24,436	18,097
Cash and Cash Equivalents [Member] | U.S. Government Agency Securities [Member]
Amortized Cost		5,818
Gross Unrealized Gains		0
Gross Unrealized Losses		0
Fair Value		5,818
Marketable Securities [Member]
Amortized Cost	28,998	15,612
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	28,998	15,612
Marketable Securities [Member] | Commercial Paper [Member]
Amortized Cost		9,794
Gross Unrealized Gains		0
Gross Unrealized Losses		0
Fair Value		$ 9,794
Marketable Securities [Member] | Corporate Debt Securities [Member]
Amortized Cost	4,562
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	$ 4,562

Note 2 - Investments and Fair_5

Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Assets, fair value	$ 54,211	$ 37,705
Liabilities, fair value	128	246
Contingent Put Option Liability [Member]
Liabilities, fair value	128	246
Fair Value, Inputs, Level 1 [Member]
Assets, fair value	25,213	3,996
Liabilities, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	28,998	33,709
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Liabilities, fair value	128	246
Fair Value, Inputs, Level 3 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	128	246
Money Market Funds [Member]
Assets, fair value	25,213	3,996
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	25,213	3,996
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Commercial Paper [Member]
Assets, fair value	24,436	27,891
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	24,436	27,891
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
U.S. Government Agency Securities [Member]
Assets, fair value		5,818
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value		0
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		5,818
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value		$ 0
Corporate Debt Securities [Member]
Assets, fair value	4,562
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	4,562
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	$ 0

Note 2 - Investments and Fair_6

Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Fair value, Beginning of period	$ 181	$ 746	$ 246	$ 437
Change in fair value of contingent put option associated with the Loan Agreement	(53)		(118)
Change in fair value of contingent put option associated with the Loan Agreement		(155)		154
Fair value, End of period	$ 128	$ 591	$ 128	$ 591

Note 3 - Inventories, Net (Deta

Note 3 - Inventories, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
ZALVISO [Member]
Inventory Write-down	$ 0	$ 300	$ 100	$ 400
Amended License Agreement [Member]
Inventory Write-down				300
DSUVIA [Member]
Inventory Write-down				$ 100

Note 3 - Inventories, Net - Inv

Note 3 - Inventories, Net - Inventory Components (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Raw materials	$ 277	$ 257
Work-in-process	0	30
Finished goods	1,086	1,339
Total	$ 1,363	$ 1,626	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 4 - Revenue From Contrac_3

Note 4 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue	$ 443	$ 2,924	$ 954	$ 3,310
DSUVIA [Member]
Revenue	392	2	573	157
ZALVISO [Member]
Revenue	0	301	270	420
Product [Member]
Revenue	392	303	843	577
Non-cash Royalty [Member]
Revenue	38	37	83	121
Royalty [Member]
Revenue	13	12	28	40
Contract and Other Collaboration [Member]
Revenue	$ 51	2,621	$ 111	2,733
Contract and Other Revenue [Member]
Revenue		$ 2,572		$ 2,572

Note 4 - Revenue From Contrac_4

Note 4 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Contract Liabilities: Deferred Revenue			$ 49
Revenue	$ 443	$ 2,924	954	$ 3,310
Contract Liabilities: Deferred Revenue, Additions			0
Contract Liabilities: Deferred Revenue, Deductions			(49)
Contract Liabilities: Deferred Revenue	0		0
Amended License Agreement [Member]
Contract Liabilities: Deferred Revenue			49
Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied	0	154	49	233
Performance obligations eliminated upon termination	0	2,572	0	2,572
New activities in the period from performance obligations satisfied: Performance obligations satisfied	0	147	221	187
Revenue	0	$ 2,873	270	$ 2,992
Contract Liabilities: Deferred Revenue, Additions			0
Contract Liabilities: Deferred Revenue, Deductions			(49)
Contract Liabilities: Deferred Revenue	$ 0		$ 0

Note 5 - Long-term Debt (Detail

Note 5 - Long-term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 01, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	May 30, 2019
Amortization of Debt Discount (Premium)				$ 430	$ 558
Leasehold Improvements [Member]
Capital Leases, Balance Sheet, Assets by Major Class, Net, Total		$ 1,700		1,700
Site Readiness Agreement [Member]
Debt Instrument, Periodic Payment, Principal	$ 500
Total Obligation Under Leasehold Agreement		$ 900		$ 900
Debt Instrument, Interest Rate, Effective Percentage		14.35%		14.35%
Warrant In Connection with Oxford Finance Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						176,679
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 2.83
Loan Agreement with Oxford Finance LLC [Member]
Debt Instrument, Face Amount						$ 25,000
Long-term Debt, Total		$ 17,200		$ 17,200
Interest Expense, Debt, Total		600	$ 900	1,200	1,700
Amortization of Debt Discount (Premium)		$ 200	$ 300	$ 400	$ 500

Note 6 - Leases (Details Textua

Note 6 - Leases (Details Textual) - USD ($)	Apr. 21, 2021	Mar. 26, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Apr. 30, 2021	Dec. 31, 2020	[1]	Feb. 16, 2019
Percentage of Office and Laboratory Space Sublease										47.00%
Gain (Loss) on Termination of Lease		$ 500,000	$ 0	$ 0	$ 522,000	$ 0
Operating Lease, Right-of-Use Asset			$ 4,607,000		$ 4,607,000			$ 3,150,000
Catalent Pharma Solutions [Member]
Commercial Supply Agreement, Term (Year)	5 years
Commercial Supply Agreement, Extended Term (Year)	2 years
Commercial Supply Agreement, Annual Fee	$ 1,000,000
Lease for Corporate Headquarters in Hayward, California [Member]
Lessee, Operating Lease, Term of Contract (Year)		2 years 3 months
Lessee, Operating Lease, Monthly Rent		$ 17,000
Lessee, Operating Lease, Abated Rent Period (Month)		1 month
Operating Lease, Right-of-Use Asset		$ 400,000
Prepaid Expenses and Other Current Assets [Member]
Lessee, Operating Sublease, Deferred Costs							$ 300,000
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 6 - Leases - Operating Lea

Note 6 - Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	Mar. 26, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating lease costs		$ 440	$ 269	$ 780	$ 609
Gain on derecognition of operating lease	$ (500)	0	0	(522)	0
Sublease income		(50)	(149)	(199)	(299)
Loss on termination of sublease		331	0	331	0
Net lease costs		$ 721	$ 120	$ 390	$ 310
Weighted-average remaining term – operating lease (in years) (Year)		5 years 4 months 28 days		5 years 4 months 28 days
Weighted-average discount rate – operating lease		12.80%		12.80%

Note 6 - Leases - Maturities of

Note 6 - Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	[1]
2021 (remaining nine months)	$ 407
2022	1,483
2023	1,144
2024	1,040
2025	1,040
Thereafter	1,454
Total future minimum lease payments	6,568
Less imputed interest	(2,453)
Total	4,115	$ 2,606
Operating lease liabilities	4,618
Operating lease liabilities, current portion	(503)	(1,118)
Operating lease liabilities, net of current portion	$ 4,115	$ 2,606
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 7 - Liability Related to_3

Note 7 - Liability Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Millions	Sep. 18, 2015	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Proceeds From Sale of Royalty and Milestone Rights	$ 65
Royalty Arrangment Maximum Payments	$ 195
Contingent Gain (Loss) on Royalty Monetization Arrangement			$ 65
Effective Interest Over Life of Liability Related to Sale of Future Royalties					0.00%
Effective Annual Interest Rate		3.60%	3.60%	3.60%	3.60%
PDL [Member]
Percentage of Royalties and Rights Under Agreement	75.00%
PDL [Member] | First Four Commercial Milestones [Member]
Percentage of Royalties and Rights Under Agreement	80.00%
Commercial Milestones Value Maximum Amount Available	$ 35.6
AcelRX [Member] | First Four Commercial Milestones [Member]
Commercial Milestones Value Maximum Amount Available	$ 44.5

Note 7 - Liability Related to_4

Note 7 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		69 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	[1]
Liability related to sale of future royalties — beginning balance			$ 88,471		$ 0
Proceeds from sale of future royalties			0		61,184
Non-cash royalty revenue			(120)		(1,058)
Non-cash interest (income) expense recognized	$ (799)	$ (834)	(1,581)	$ (1,677)	26,644
Liability related to sale of future royalties as of June 30, 2021	86,770		86,770		86,770
Less: current portion	0		0		0
Liability related to sale of future royalties — net of current portion	$ 86,770		$ 86,770		$ 86,770	$ 88,365
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 8 - Legal Proceedings (Det

Note 8 - Legal Proceedings (Details Textual)	Jul. 06, 2021	Jun. 08, 2021
Purported Shareholder v. Company - Violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 [Member]
Loss Contingency, Number of Defendants		2
Purported Shareholder v. Company - Alleged Misstatements as the Shareholder [Member] | Subsequent Event [Member]
Loss Contingency, Number of Defendants	10

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jun. 17, 2021	Jan. 27, 2021	Jan. 27, 2021	Jan. 22, 2021	May 09, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 16, 2020
Proceeds from Issuance of Common Stock								$ 36,360	$ 1,449
The 2020 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	4,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)										5,500,000
The 2020 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	4,300,000
Private Placement [Member] | Armistice Capital and Rock Springs Capital [Member]
Stock Issued During Period, Shares, New Issues (in shares)		16,675,000	2,175,000	14,500,000
Shares Issued, Price Per Share (in dollars per share)		$ 1.7625	$ 1.7625	$ 1.7625
Proceeds from Issuance of Common Stock		$ 28,900
ATM Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						3,000,000	445,000	3,000,000	876,800
Aggregate Offering Price, Maximum					$ 80,000			$ 36,100
Proceeds from Issuance of Common Stock, Net						$ 7,500	$ 700	$ 7,500	$ 1,500

Note 10 - Stock-based Compens_3

Note 10 - Stock-based Compensation (Details Textual) - The 2020 Equity Incentive Plan [Member]	Jun. 30, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	7,589,292
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	14,790,044
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	1,834,228

Note 10 - Stock-based Compens_4

Note 10 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Stock-based compensation expense	$ 1,172	$ 1,090	$ 2,261	$ 2,236
Cost of Sales [Member]
Stock-based compensation expense	21	27	43	73
Research and Development Expense [Member]
Stock-based compensation expense	200	184	381	384
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 951	$ 879	$ 1,837	$ 1,779

Note 11 - Net Loss Per Share _3

Note 11 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
RSU's, ESPP, and Employee Stock Options [Member]
Antidilutive securities (in shares)	16,907,412	14,816,721
Warrant [Member]
Antidilutive securities (in shares)	176,679	176,679

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - Jul. 14, 2021 - Aguettant [Member] - Subsequent Event [Member] € in Millions, $ in Millions	USD ($)	EUR (€)
DZUVEO [Member]
License Agreement, Term (Year)	10 years
License Agreement, Renewal Term (Year)	5 years
License Agreement, Upfront and Maximum Milestone Payments to be Received | €		€ 47
DZUVEO [Member] | Minimum [Member]
License Agreement, Percent of Revenue Share Payments to be Received	35.00%
DZUVEO [Member] | Maximum [Member]
License Agreement, Percent of Revenue Share Payments to be Received	45.00%
PFS Products [Member]
License Agreement, Term (Year)	10 years
License Agreement, Renewal Term (Year)	5 years
License Agreement, Milestone Payments to be Paid, Maximum | $	$ 24
License Agreement, Minimum Sales Obligation Term (Month)	12 months
PFS Products [Member] | Minimum [Member]
License Agreement, Percent of Revenue Share Payment to be Paid	40.00%
PFS Products [Member] | Maximum [Member]
License Agreement, Percent of Revenue Share Payment to be Paid	45.00%